Rhythm Pharmaceuticals, Inc. (RYTM)
收市後：
| 前收市價 | 37.96 |
| 開市 | 37.98 |
| 買盤 | 38.95 x 100 |
| 賣出價 | 48.93 x 200 |
| 今日波幅 | 37.65 - 39.06 |
| 52 週波幅 | 15.50 - 52.57 |
| 成交量 | |
| 平均成交量 | 577,583 |
| 市值 | 2.376B |
| Beta 值 (5 年，每月) | 1.93 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.63 |
| 業績公佈日 | 2024年7月30日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 57.22 |
Insider MonkeyRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript May 7, 2024 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-2.35058 EPS, expectations were $-2.12. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
InvestorPlaceThe 3 Best Nasdaq Stocks to Buy in May 2024
While conventional wisdom calls for selling securities, these best Nasdaq stocks may require a complete rethink. With the possibility that the Federal Reserve might get its soft landing after all, risk-on sentiment has returned on Wall Street. Previously, the combination of consistently robust jobs reports and soaring energy prices meant that the central bank would likely have been forced to shift its policy. Rather than cutting interest rates, the Fed appeared to be on course to raise them. How
ZacksRhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
